Pharmacological approaches to COVID-19 encompass drug development, repurposing, and optimization strategies for prevention and treatment. This includes antiviral agents, immunomodulatory, monoclonal antibodies, and supportive therapies. Clinical research has rapidly evolved to identify effective treatments for different stages of the disease. Pharmacology also plays a role in vaccine adjuvant design, pharmacokinetics of antiviral combinations, and management of post-COVID complications. Ongoing studies address emerging variants, resistance, and long-term safety of COVID-19 therapeutics.
Sub tracks:
Related Conferences:
World Congress on Pharmacology & Toxicology (WCPT) | International Conference on Clinical Pharmacology & Therapeutics (ICCPT) | Global Summit on Drug Discovery and Development (GSDDD) | European Conference on Toxicology & Applied Pharmacology (ECTAP) | International Symposium on Experimental and Clinical Toxicology (ISECT)
Related Associations:
International Union of Basic and Clinical Pharmacology (IUPHAR) | British Pharmacological Society (BPS) | American Society for Pharmacology and Experimental Therapeutics (ASPET) | European Society of Toxicology (EUROTOX) | Society of Toxicology (SOT) | Asia Pacific Association of Pharmacologists (APAP) | Federation of Asian Pharmacological Societies (FAPS) | International Society for the Study of Xenobiotics (ISSX)
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
